Sbi Securities Co., Ltd. Enlivex Therapeutics Ltd. Transaction History
Sbi Securities Co., Ltd.
- $3.9 Trillion
- Q3 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 1 shares of ENLV stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ENLV
# of Institutions
32Shares Held
930KCall Options Held
0Put Options Held
0-
Citizens Financial Group Inc231KShares$226,7950.0% of portfolio
-
Morgan Stanley New York, NY174KShares$170,1520.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$154,1460.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il68.9KShares$67,5570.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA54.9KShares$53,7530.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $18M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...